Mode of alloantibody-mediated blockade of allo-sensitization for tumor allograft rejection.
The mode of alloantibody-mediated inhibition of allo-sensitization for tumor allograft rejection was studied. Relatively small amounts of anti-H-2d alloantiserum administered shortly before or after injection of allogeneic spleen cells blocked the allo-sensitization for second-set tumor allograft rejection. In contrast, the alloantiserum injected shortly before inoculation of tumor barely enhanced the tumor growth. The passively administered alloantiserum inhibited the sensitization for allospecific cytotoxic T lymphocyte responses in vitro. Further study revealed that the allo-sensitization could be blocked with antiserum specific against only one of the expressed H-2 antigens on stimulator cells. Correspondingly, H-2Dd-monospecific monoclonal antibody (IgG2a) was effective in inhibiting the sensitization with cells expressing multiple H-2 alloantigens. These results suggest that antibody-mediated inactivation of stimulator cells as a whole is an important mechanism of the allograft enhancement.
Lai
H
H
Department of Immunology, Nagoya University School of Medicine, Japan.
Hasegawa
Y
Y
Mizoguchi
K
K
Yoshida
T
T
Isobe
K
K
Shimokata
K
K
Kawashima
K
K
Nakashima
I
I
D000818:Animals; D000911:Antibodies, Monoclonal; D001667:Binding, Competitive; D006084:Graft Rejection; D006183:H-2 Antigens; D007518:Isoantibodies; D007939:Leukemia L1210 / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D006183:H-2 Antigens; D007518:Isoantibodies